Patients in need of cataract surgery also see their risk for developing dementia drop by 30% after undergoing the operation, according to new research published today in JAMA Internal Medicine.
UW Medicine was one of the clinical trial sites for aducanumab, a drug approved yesterday by the Food and Drug Administration to slow the progression of Alzheimer’s disease in people with mild symptoms.